Proteomics as a Future Tool for Improving IVF Outcome by Mitulović, Goran & Panić-Janković, Tanja
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Proteomics as a Future Tool for 
Improving IVF Outcome
Goran Mitulović and Tanja Panić-Janković
Abstract
New technical and methodical and more efficient approaches beyond pre-
implantation genetic screening (PGS) are needed to elevate success rates in 
in vitro fertilization (IVF). One new approach could be the characterization of 
the embryos’ proteome during the IVF process. This means that specific proteins 
secreted by the embryo in the surrounding cultivating medium can be analyzed and 
compared between embryos in order to identify potential markers for a successful 
embryo transfer and resulting pregnancy. Furthermore, this procedure could result 
with understanding the processes during the whole time of incubation, from the 
moment of oocyte fertilization until embryo transfer and subsequently implanta-
tion by analyzing the culturing medium used in multiple culture medium exchange 
during the cultivation period. This procedure of embryo transfer to a new culture 
medium is essential for the embryo’s development and is performed daily or at 
least when the embryos reached the stage of embryoblast at day 4. The remaining 
medium after embryo removal is routinely discarded. However, this medium still 
can be useful for a detailed analysis of proteins and lipids that were secreted by the 
embryo during the previous incubation process and could help gaining information 
on the embryos’ current developmental status.
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1. Introduction
The European Society of Human Reproduction and Embryology (ESHRE) 
report from February 2018 shows that Europe continues to lead the world with 
approximately 50% of all reported in vitro fertilization (IVF) cycles. The lat-
est figures are available for 2014, and these show that 39 European countries 
reported almost 800.000 cycles, which compare to 150.000 cycles in the USA 
or 65.000 cycles in Australia and New Zealand (https://www.eshre.eu/~/media/
sitecore-files/Guidelines/ART-fact-sheet_vFebr18_VG.pdf?la=en). Although there 
are no official reports from China, it is estimated that this country performs more 
than 800.000 IVF cycles with a tendency to grow. In summary, the ESHRE esti-
mates that around 2.5 million IVF cycles is performed every year and that about 
500.000 babies are born following the IVF.
The pregnancy rate depends on the embryo quality, and in Europe in 2014, 
the mean pregnancy rate per embryo transfer was 35% after IVF, 33% after ICSI, 
30% after frozen embryo transfer, and 59% after egg donation. It is observed that 
pregnancy rates are higher in younger patients (<35 years).
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There are large differences between countries concerning the number of 
embryos transferred and the resulting multiple births that can occur following the 
multiple embryo transfer. Multiple pregnancies are classified as high-risk preg-
nancies and pose a significant health risk to both the mother and baby. However, 
regardless of that, the practice of multiple embryo transfer is still present, and it is 
being widely used in order to increase the chances of pregnancy. Currently, efforts 
are made to reduce the number of multiple embryo transfer, and a mean of 1.81 
embryos per transfer is being reported. In Europe, according to the report of the 
European Society of Human Reproduction and Embryology, the number of mul-
tiple delivery rates for embryo transfers dropped from 26.9% in year 2000 to 17.5% 
in 2014 (latest data available), and it is expected to decline further. Some countries, 
e.g., Sweden, has reached a very low multiple delivery rate, and the single embryo 
transfer was performed in more than two-thirds of all transfers.
The importance of IVF in society is also highlighted by the 2010 Nobel Prize 
which has been awarded to Robert Edwards who is, together with Robert Steptoe, 
the “father” of the fist “IVF-Baby.”
The IVF process is an utmost stressful, both physically and psychologically, for 
both parents but primarily for the mother-in-being. A number of physical exami-
nations and medical procedures are being performed in order to ensure that the 
process will lead to a successful pregnancy.
During the IVF process, especially when decisions are made which embryo shall 
be transferred in order to ensure the greatest chance for success, the best possible 
decision, based on the fast and accurate information on the status of the embryo, is 
needed. Due to the increasing age of mothers-to-be, during the past years, a steady 
increase in pregnancies following artificial reproductive techniques (ART), namely, 
IVF and intra-cytoplasmatic sperm injection (ICSI), was observed. The reasons for 
this development must be seen in economic, educational, and social factors, which 
lead to steadily rising rates of elderly patients. With increasing age, fecundability 
and fertility decrease. However, the advances made in reproductive medicine itself 
might be one of the reasons, why an increasing number of women delay childbear-
ing, hoping for late babies and consciously making decisions to use the help of 
reproductive medicine.
The elevation of pregnancy rates for IVF procedures is certainly needed in order 
to reduce the burden on patients and lower costs affiliated with the procedures, 
which very often must be repeated until a pregnancy is reached and the embryo 
develops to successful birth. New technologies and methods more efficient than the 
current approach using PGS are needed. One new approach could be the analysis of 
the embryos’ proteome during the IVF process. This means to analyze the specific 
proteins that are secreted by the embryo in the IVF surrounding of the culture 
medium. Routinely, the medium left after embryo transfer is being discarded. The 
multiple embryo transfer occurring during the IVF procedure is necessary after the 
fertilization step, and the spent media are a rich source of biological material that 
can be used for diagnostic purpose. This procedure of embryo transfer to a new 
culture medium is essential for the embryo’s development and occurs daily or at 
least when the embryos have achieved the stage of embryoblast at day 4.
The spent medium can be useful for a detailed examination of proteins and 
lipids that were secreted by the embryo during each stage of development and can 
be used for the estimation of the “embryo quality” and selection of corresponding 
embryos for primary transfer.
An overview of technologies and approaches being used and a simplified experi-
mental approach are presented in this chapter. The method used in our laboratory 
is used just as an example of the technologies used, and a number of different 
approaches will be discussed.
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2. Materials and methods
2.1 Analyzed embryo cultivation medium: source of the material
Embryo cultivation medium is usually being discarded during the IVF proce-
dure although it can be used for multiple diagnostic and prognostic procedures. 
Certainly, ethical and moral guidelines and procedures must be observed, and the 
ethical board or other corresponding bodies must approve of the use of this mate-
rial. The following experiments have been performed by using cultivation media 
from IVF media upon approval from the ethical boards of the Medical University 
in Vienna and the University of Linz in Austria. Samples were collected during dif-
ferent stages of embryo development and analyzed using methods established for 
analysis of low samples amounts.
2.2 Proteomics sample preparation
Trypsin for protein digestion was purchased from Promega Inc. (Vienna, 
Austria). Solvents for HPLC—methanol (MeOH), acetonitrile (AcN), 2,2,2-tri-
fluoroethanol (TFE), formic acid (FA), heptafluorobutyric acid (HFBA), iodoacet-
amide (IAA), triethylammonium bicarbonate (TEAB), and dithiothreitol—were 
purchased from Sigma-Aldrich (Vienna, Austria).
One of the most important steps when analyzing embryo cultivation media 
is the depletion of serum albumin present in these samples. Tarasova et al. [1] 
described the innovative method of using immobilized antihuman albumin 
antibodies for depletion of small sample volumes. Briefly, for depletion of 
culture media samples from selected embryos, the sample was diluted using the 
phosphate buffered saline buffer (pH 7.4) consisting of 0.01 M phosphate buffer, 
0.0027 M KCl, and 0.14 M NaCl. This buffer was further also used as a washing 
buffer A upon the sample loading. In order to ensure full sample recovery from 
the depletion column, a ready-to-use elution buffer from Agilent (pH 2.25) 
(Agilent Technologies, CA, USA) was used as buffer B. We have developed a new 
column for the depletion of human albumin by immobilizing the antihuman 
albumin antibodies to the monolithic support disk, the CIMac-HSA column, 
especially for analysis of small sample amounts, which also occur in IVF samples. 
This column was used in an ICS-5000 inert HPLC system (Dionex-Thermo 
Scientific, Germering, Germany) for albumin depletion with a column flow 
rate of 0.3 mL/min. Upon sample injection, the loading and washing buffer A 
was pumped through the column for 5 min, and the flow-through fraction was 
collected (V = 350 μL). This fractions’ volume corresponds to the full absorbance 
peak and contains all proteins that were not trapped on the column. The albumin 
was trapped by the interaction with the antibodies on the column’s surface, and 
it was eluted by increasing the amount of the eluting mobile phase from 5 to 
10 min. The column was, finally, flushed with the loading buffer A for additional 
4 min, and this step was followed by an additional washing step with buffer B 
and, finally, equilibrating step using, again, the loading buffer A for 13 min. The 
total time for completing this depletion protocol is 30 min when applying the 
column flow rate of 0.3 mL/min. During this time, the very important column 
wash step and the complete re-equilibration of the column preceding the next 
depletion run is being perfromed. The flow rate used was selected for maximiz-
ing the protein’s interaction time and was a compromise between the speed and 
efficacy of operation. If desired, higher column flow rates can be used without 
losing much of the column’s performance [2], but this shall be carefully examined 
and optimized.
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Proteins in both collected fractions and non-depleted samples were depleted 
using a standard protocol with trypsin. Due to a high concentration of phosphate 
buffer in collected fractions, 1 M triethylammonium bicarbonate (TEAB) was 
added to the fractions in order to reach a final concentration of 50 mM TEAB and to 
dilute the phosphate buffer. For protein denaturation, 10 μL of 0.1% (w/v) Rapigest 
in 50 m MTEAB were added to all fractions, and reduction of disulfide bonds was 
performed using dithiothreitol (final concentration of 5 mM DTT) and incubating 
the reaction mixture for 30 min at 60°C.
For a successful trypsinization, alkylation was performed using iodoacetamide 
at a final concentration of 15 mM IAA. Upon addition of IAA, the sample was 
incubated at room temperature, in the dark, for 30 min. An excess of iodoacetamide 
is inhibiting the trypsin action and needs to be neutralized, which was achieved by 
adding 2 μL of 50 mM DTT in 50 mM TEAB, vigorous mixing for 2 min at room 
temperature. Finally, 10 μL of 0.2 μg/μL trypsin solution were added, and samples 
were incubated for 16 h at 37°C in an incubation oven. Tryptic activity was stopped 
by acidifying the solution with 1% TFA solution.
For LC–MS/MS analysis, 20 μL of the digested and diluted sample (aqueous 
0.1% TFA at a ratio of 2:3 (v/v)) were injected for LC–MS/MS analysis.
2.3 Chromatographic separation and mass spectrometry detection
A Dionex UltiMate 3000 RSLC nanoLC system (Dionex-Thermo Scientific) was 
used for the nanoHPLC separation of tryptic peptides. Mobile phases used for chro-
matographic separation of tryptic peptides were as follows: (A) 5% of acetonitrile in 
aqueous 0.1% formic acid and (B) methanol, trifluoroethanol, water and acetonitrile 
(30:10:10:50 (v/v/v/v) and 0.1% of formic acid). The sample was loaded onto the trap 
column for washing the residula salts and focusing of the analytes as a small sample 
front by using loading mobile phase consisting of 0.1% aqueous TFA chilled to 3°C.
The nonlinear gradient of 75 min total running time was used for HPLC separa-
tions of tryptic peptides. The gradient was composed using sequential linear steps:
1. 1.0% B min−1 for 7 min.
2. 0.5% B min−1 gradient for 38 min.
3. 1.5% B min − 1 for 20 min.
4. 3.0% B min−1 for 10 min.
The HPLC flow was introduced into the maXis Impact UHR TOF mass spec-
trometer (Bruker Daltonics, Bremen, Germany), and the LC–MS/MS analysis 
was performed in triplicate for each sample. For peptide fragmentation (MS/MS), 
collision-induced dissociation was used, and all MS/MS data were acquired in a 
300–2000 m/z range using a three-second cycle without further optimization of 
the instrument’s parameters. In order to prevent unnecessary fragmentation of ions 
with low intensity, the lower threshold for precursor ions was set to 1000 counts. 
Due to tailing of some peptides and frequently observed co-elution of peaks, a 
dynamic exclusion was employed, and the duration was set to 120 s. In case where 
the precursor ion showed higher intensity after the exclusion period of 120 s, it was 
reconsidered for an additional MS/MS event.
Database search for protein identification was performed using the all-taxonomy 
Swiss-Prot database (http://www.uniprot.org). For this search, X! Tandem [3] with 
following parameters was used:
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1. Precursor mass tolerance of ±10 ppm.
2. Fragment mass tolerance of ±0.3 Da.
3. Maximum of two missed cleavages were allowed.
Some posttranslational modifications of peptides due to the sample preparation 
and due to biological processes can be expected. For the experiment described, cys-
teine carbamidomethylation was selected as the fixed modification and methionine 
oxidation; phosphorylation of serine, threonine, and tyrosine residues, as well as the 
acetylation of lysine and N-terminal residues, were selected as variable modifications.
2.4 Data analysis
All data analysis for the experiments described in this manuscript was analyzed 
using the method described by Tarasova et al. [1]. The use of pyteomics.pepxmltk 
converter (https://pypi.python.org/pypi/pyteomics.pepxmltk) and search was 
described elsewhere [4]. Briefly, this platform was used to convert X! Tandem files 
to the standard pep.xml format and perform data analysis. All identifications, upon 
database search, were filtered to meet the requirement of the 1.0% FDR at peptide 
level. Search results were submitted for a post-search validation using the MPscore 
software, described earlier [5]. Quantitative information on identified proteins is a 
substantial requirement for determining the differences between biological sam-
ples, and all proteins fulfilling the identification and validation requirements were 
quantified using the label-free quantitation approach called normalized spectral 
index (SIn) (Griffin et al.) [6].
3. Results and discussion
3.1 Albumin depletion in IVF cultivation medium
The presence of albumin in cultivating medium is necessary for the normal 
development of embryos. However, its presence is a significant burden for pro-
teomics analysis, and it must be removed prior to further analysis steps. The 
removal of albumin has been extensively discussed and described in a number of 
publications [1, 2, 7–9]. Different groups have used a number of methods such as 
immunodepleting chromatography, molecular weight cutoff filters, peptide librar-
ies, size exclusion chromatography, etc. All these methods have some advantages 
but also show disadvantages. In case of depleting the albumin from IVF cultivat-
ing medium, the very low sample volume (max. of 40 μl) must be taken into 
consideration. Furthermore, depletion method must be performed fast and must 
be reproducible over a large number of samples, if intended to be used for fast 
analysis of clinical samples that shall help making the decision on which fertilized 
oocyte shall be transferred first and which ones shall be frozen for later procedures. 
The use of a novel immunoaffinity-based convective interaction media analytical 
columns (CIMac) for depletion of HSA (CIMac-HSA) was performed in this study, 
and it proved that it can be used for fast and reproducible albumin depletion from 
minute sample amounts. The column’s architecture and the convective flow-through 
columns’ channels enable a flow rate-independent binding capacity and excellent 
chromatographic resolution. These characteristics give CIMac-αHSA column some 
important analytical benefits like shorten time of analysis in comparison to com-
mon chromatographic depletion of albumin using silica-based columns, which 
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is an extraordinary important parameter for clinical use. The albumin content in 
different batches of cultivating medium differs strongly, and it also differs strongly 
between different suppliers. Therefore, the depletion method must be selected in 
a way that can be applied for a variety of samples. However, independently of the 
selected methods, the removal of albumin from the cultivating medium results with 
a number of identified proteins of which some can be of importance for embryo 
development and for later pregnancy development.
Figure 1 shows two SDS-gel lanes for the separation of two media upon 
embryo transfer. Since albumin originates from different donors and is being 
mixed at the manufacturing site, it will certainly contain a number of other 
proteins that may interfere with proteins secreted from the developing embryo. 
Also, secreted proteins might bind on albumin and, therefore, be “invisible” for 
proteomics analysis.
In addition to that, the human proteome, as any proteome, is dynamic, and 
it is constantly changing through internal and external stimuli. Proteins being 
translated from RNA are directly responsible for cellular function, but different 
gene expression studies have, unfortunately, shown that a reliable prediction of 
proteins’ function or abundance cannot be made. As for the human proteome, 
significant advances have been made for the analysis of the whole proteome and 
of the proteome of different disease states [3, 5, 10–20]. Bearing all of it in mind, 
the analysis of proteins obtained from the cultivating media is challenging, and the 
results are not always conclusive.
Figure 2 shows the results obtained upon analyzing four different cultivating 
media used in routine IVF procedures and upon embryo transfer.
Dyrlund et al. [21] have performed the analysis of unconditioned commercial 
embryo culture media and have identified a number of proteins upon depletion 
and digestion of a total of 5 mL of media. The amount of 5 mL, however, will never 
be available if samples are retrieved during the actual IVF process. However, this 
analysis showed that this amount contains an astounding amount of 25 mg of albu-
min. Here, a total of 111 proteins with different concentrations in different batches 
of the media were identified in addition to albumin. The sample of unconditioned 
media also contained eight proteins previously suggested as possible markers of 
Figure 1. 
Lanes 2 and 4 show an example of the separation of proteins secreted in culturing media on silver-stained SDS 
gel. As expected, large spots for human serum albumin (HSA) are observed for both samples with significantly 
lower amounts of other proteins. Since the culturing media have been declared to contain only HSA, the 
proteins below are secreted from the fertilized oocyte (lane 2) and unfertilized oocyte (lane 4).
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embryonic viability, e.g., proteoglycan-4, serotransferrin, vitamin-D-binding 
protein, ubiquitin, etc.
Another study performed on IVF medium examined the batch-to-batch varia-
tions and showed that variation in both protein amounts and protein identifications 
can be expected [22]. When studying these media, it is important to pay attention 
to the fact that both media, the control and the media where embryos grow, must be 
from the same batch in order to make valid comparison.
Spent IVF medium is a valuable source for proteins that can be used as putative 
biomarkers in IVF. The major focus of researchers has been on secreted proteins, 
but the proteins already present in the medium can be equally valuable and must 
be considered in the pursuit for biomarkers of embryos’ “quality.” It is very possible 
that proteins already present in the medium may be necessary for embryo develop-
ment, and the uptake or degradation of specific proteins might correlate to ascer-
tain embryo development or lack thereof. Therefore, these media must be evaluated 
for their potential to differentiate embryos’ success rates and track the proteins, 
which can be potential biomarkers. Additionally, the safety of these proteins in 
culture media for the offspring should also be evaluated.
Figure 2. 
Identified proteins and their relative quantities in albumin-free fractions after performing albumin depletion 
of culturing media samples on two different depletion columns. Proteins identified either in the CIMac-αHSA 
FT or the Seppro FT1 fractions are labeled with B and S, followed by Swiss-Prot protein ID. Median values of 
normalized spectral indexes (SI) and standard deviations are shown. Median SIHSA in non-depleted samples 
is marked with red dashes. More than two peptide-spectrum matches were assumed for each of the listed 
proteins according to Tarasova et al. [1].
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3.2  Identification of proteins in IVF cultivation medium and their possible role 
for embryo development
Proteins identified by Dyrlund et al. were also reported by Katze-Jaff upon 
analysis of the secretome of the individually cultured human embryos, and a hint 
was made that these proteins could be related to embryo’s morphology and thus its 
viability [23–25]. They have reported that ubiquitin was upregulated in developing 
blastocytes as compared to degenerating blastocytes. However, there was no cor-
relation between the ubiquitin upregulation and the observed pregnancy rates.
Cortezzi et al. [26] reported the identification of proteins in both positive and 
negative groups of embryos, i.e., embryos termed viable for transfer and does 
who were not selected. For positive-implantation group, protein, called Jumonji 
(JARID2), was reported. This protein composes a histone methyltransferase 
complex called polycomb repressive complex 2 (PRC2), which modifies chromatin 
methylation to silence many embryonic patterning genes, acting as a negative regu-
lator of cell proliferation signaling. This results with a restricted gene expression 
to an appropriate cell population that is essential for development, differentiation, 
and maintenance of cell fates.
In the same study, the testis-specific gene 10 protein (TSGA10) was identified 
only in negative samples. TSGA10 is a perinuclear protein, and it was described to 
participate in actively dividing and fetal differentiating tissues in mice embryos.
Katz-Jaffe et al. reported the identification of heparin-binding epidermal 
growth factor EGF-like growth factor precursor (HB-EGF) [24]. This growth factor 
precursor belongs to the EGF family growth factors, and it is found in the mem-
brane-anchored form (proHB-EGF) and the soluble form (sHB-EGF). The soluble 
form is produced from the proteolytic cleavage of proHB-EGF at the extracellular 
domain. Furthermore, soluble HB-EGF has been observed to be a growth stimula-
tor, and it does significantly improve the blastocyst development and hatching 
when added to serum-free medium. However, other studies from an in vitro model 
system indicate that proHB-EGF might function in cell-to-cell signaling by a juxta-
crine mechanism inhibiting growth activity [27]. Since this protein was identified 
in degenerating blastocytes, its upregulation might contribute to the lack of further 
development.
A cystatin-like precursor is needed for successful mammalian implantation for 
a controlled trophoblastic invasion of the maternal uterine epithelium. It must be 
available and functional [28] since this invasion involves the extracellular degrada-
tion of the uterine matrix by a variety of proteinases, and one of the crucial ones are 
cysteine proteinases. Cystatins are known to inhibit cysteine proteinases, and their 
upregulation will most probably contribute to failure of implantation of degenerat-
ing blastocysts. Therefore, it is not only of importance to identify these proteins, the 
possible biomarkers, but also to validate these findings in the human.
4. Conclusion
Proteomics is a promising technology for the identification and validation of 
possible biomarkers for embryo selection in ART. As listed by Dyrlund et al., a 
growing list of secreted proteins has been identified that could further contribute 
to this field [21]. However, the challenge ahead of the research still includes the 
reliable and reproducible identification of a proteomics secretome signature. This 
signature shall be directly associated with embryo viability and the success of the 
procedure, i.e., successful pregnancy, and child’s birth. This is a very challenging 
task not only due to the complexity, heterogeneity, and diversity of human embryos 
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but also because of irreproducibility of used culturing media and contaminant 
proteins therein.
Another challenge for the clinical use of proteomics methods is the speed of the 
proteomics analysis. Sample preparation, measurement, and data analysis of a sam-
ple is currently not feasible within the time window needed for IVF. Current sample 
analysis methods require at least half a day for the fastest proteomics method avail-
able, which is too long. Nevertheless, proteomics methods can contribute to identi-
fication and validation of putative biomarkers, which once clinically confirmed, can 
be analyzed using other, faster, methods upon building corresponding antibodies.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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